Nektar Therapeutics - NKTR Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price targets for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.50 to $6.00. On average, they expect the company's stock price to reach $3.08 in the next year. This suggests a possible upside of 338.7% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 68.9% and is now trading at $0.7029.
View the best growth stocks for 2023 here.

Nektar Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 7,080,000 shares, a decline of 19.1% from the February 28th total of 8,750,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the short-interest ratio is currently 2.9 days.
View Nektar Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our NKTR earnings forecast.

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company had revenue of $22.02 million for the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative net margin of 399.98% and a negative trailing twelve-month return on equity of 76.92%. Nektar Therapeutics's revenue for the quarter was down 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.79) earnings per share.

ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).AdvisorShares Dorsey Wright Short ETF (DWSH) and

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NKTR stock can currently be purchased for approximately $0.70.

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $133.01 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

The company employs 740 workers across the globe.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.